Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...

Topline results from our Phase 2 BMT-801 'signal detection' clinical study with MC4R agonist bremelanotide plus a glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

In today’s fast-paced world, managing weight and metabolic health has become a crucial concern for many. With the rise of obesity and related health issues, effective solutions are in high demand.

Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1 ... other costimulatory and inhibitory interactions regulate T-cell responses.

Stress hormones ... cells for direct cell destruction or elimination and the release of cytokines to enhance and expand the immune effects. T cells can be roughly classified into the cytotoxic T cells ...

A collaborative research team led by Professor Jinah Jang from the Department of Mechanical Engineering and the Department of ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner.

GLP-1 stands for glucagon-like peptide-1, a hormone that ... suppresses the release of glucagon (a hormone that raises blood sugar), and slows gastric emptying. These actions help regulate blood ...

A brand new candidate for weight-loss treatment is on the table, with scientists uncovering for the first time how a hormone ...